| Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV S Hosseini-Hooshyar, M Martinello, J Yee, P Read, D Baker, JJ Post, ... Aids 34 (9), 1347-1358, 2020 | 25 | 2020 |
| Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort JM Carson, B Hajarizadeh, J Hanson, J O'Beirne, D Iser, P Read, ... International Journal of Drug Policy 96, 103422, 2021 | 24 | 2021 |
| Hepatitis C virus reinfection following direct-acting antiviral treatment in the prison setting: the SToP-C study JM Carson, GJ Dore, AR Lloyd, J Grebely, M Byrne, E Cunningham, ... Clinical Infectious Diseases 75 (10), 1809-1819, 2022 | 21 | 2022 |
| High Effectiveness of Broad Access Direct‐Acting Antiviral Therapy for Hepatitis C in an A ustralian Real‐World Cohort: The REACH‐C Study J Yee, JM Carson, B Hajarizadeh, J Hanson, J O’Beirne, D Iser, P Read, ... Hepatology communications 6 (3), 496-512, 2022 | 17 | 2022 |
| Optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis C virus infection in Australia: a model-based cost-effectiveness analysis STF Shih, Q Cheng, J Carson, H Valerio, Y Sheehan, RT Gray, ... The Lancet Regional Health–Western Pacific 36, 2023 | 14 | 2023 |
| Retreatment for hepatitis C virus direct‐acting antiviral therapy virological failure in primary and tertiary settings: The REACH‐C cohort JM Carson, B Hajarizadeh, J Hanson, J O'Beirne, D Iser, P Read, ... Journal of viral hepatitis 29 (8), 661-676, 2022 | 11 | 2022 |
| National trends in retreatment of HCV due to reinfection or treatment failure in Australia JM Carson, S Barbieri, GV Matthews, GJ Dore, B Hajarizadeh Journal of Hepatology 78 (2), 260-270, 2023 | 7 | 2023 |
| Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a … R Sacks-Davis, DK van Santen, A Boyd, J Young, A Stewart, JS Doyle, ... The Lancet HIV 11 (2), e106-e116, 2024 | 4 | 2024 |
| Reinfection incidence and risk among people treated for recent hepatitis C virus infection M Martinello, JM Carson, M Van Der Valk, JK Rockstroh, P Ingiliz, ... Aids 37 (12), 1883-1890, 2023 | 4 | 2023 |
| Incidence of hepatitis C virus infection in the prison setting: The SToP‐C study B Hajarizadeh, JM Carson, M Byrne, J Grebely, E Cunningham, J Amin, ... Journal of Viral Hepatitis 31 (1), 21-34, 2024 | 3 | 2024 |
| Hepatitis C virus reinfection in a real-world cohort of homeless-experienced individuals in Boston ME Beiser, LC Shaw, SK Shores, JM Carson, B Hajarizadeh Clinical Infectious Diseases 77 (1), 46-55, 2023 | 3 | 2023 |
| Increasing national trend of direct-acting antiviral discontinuation among people treated for HCV 2016–2021 J Carson, S Barbieri, GV Matthews, GJ Dore, B Hajarizadeh Hepatology Communications 7 (4), e0125, 2023 | 3 | 2023 |
| Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: the REACT study JM Carson, S Barbieri, E Cunningham, E Mao, M van der Valk, ... Journal of the International AIDS Society 26 (9), e26168, 2023 | 1 | 2023 |
| Effectiveness of direct‐acting antiviral therapy among Aboriginal and Torres Strait Islander peoples with HCV infection in Australia: A national real‐world cohort (REACH‐C) J Hudson‐Buhagiar, J Carson, S Monaghan, P Collie, R Nelson, ... Journal of Viral Hepatitis 30 (5), 386-396, 2023 | 1 | 2023 |
| Contribution of prison-based hepatitis C treatment initiations to overall treatment uptake in Victoria, Australia S Griffin, AL Wilkinson, R Winter, B Hajarizadeh, M MacIsaac, T Papaluca, ... The Lancet Regional Health–Western Pacific 48, 2024 | | 2024 |
| Screening for Hepatitis C Virus Reinfection Using a Behaviour-Based Risk Score among Men Who Have Sex with Men with HIV: Results from a Case–Control Diagnostic Validation Study K Hage, M van de Kerkhof, A Boyd, JM Carson, AM Newsum, A Matser, ... Pathogens 12 (10), 1248, 2023 | | 2023 |
| Optimizing Hepatitis C Testing Strategy in High Priority Populations: A Cost-Effectiveness Analysis STF Shih, Q Cheng, J Carson, H Valerio, Y Sheehan, R Gray, ... 2023 World Congress on Health Economics, 2023 | | 2023 |
| Corrigendum to ‘National trends in retreatment of HCV due to reinfection or treatment failure in Australia’(J Hepatol [2023] 260–270) JM Carson, S Barbieri, GV Matthews, GJ Dore, B Hajarizadeh Journal of Hepatology 78 (5), 1084, 2023 | | 2023 |
| National trends in retreatment of HCV due to reinfection or treatment failure in Australia (vol 78, pg 260, 2023) JM Carson, S Barbieri, G V Matthews, GJ Dore, B Hajarizadeh JOURNAL OF HEPATOLOGY 78 (5), 1084-1084, 2023 | | 2023 |
| Screening for Hepatitis C Virus Reinfection Using a Behaviour-Based Risk Score among Men Who Have Sex with Men with HIV: Results from a Case–Control Diagnostic Validation Study … K Hage, M van de Kerkhof, A Boyd, JM Carson, AM Newsum, A Matser, ... | | 2023 |
